Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth (Status and Outlook) 2025-2031
Description
The global Antibody-drug Conjugates (ADCs) CMO and CDMO market size is predicted to grow from US$ 4422 million in 2025 to US$ 13010 million in 2031; it is expected to grow at a CAGR of 19.7% from 2025 to 2031.
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
United States market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Antibody-drug Conjugates (ADCs) CMO and CDMO players cover Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates (ADCs) CMO and CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates (ADCs) CMO and CDMO sales for 2025 through 2031. With Antibody-drug Conjugates (ADCs) CMO and CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates (ADCs) CMO and CDMO industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates (ADCs) CMO and CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-drug Conjugates (ADCs) CMO and CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates (ADCs) CMO and CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates (ADCs) CMO and CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates (ADCs) CMO and CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates (ADCs) CMO and CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cleavable linkers
Non-cleavable linkers
Segmentation by Application:
Solid Tumors
Hematological Malignanciesncies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Please note: The report will take approximately 2 business days to prepare and deliver.
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
United States market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Antibody-drug Conjugates (ADCs) CMO and CDMO players cover Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates (ADCs) CMO and CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates (ADCs) CMO and CDMO sales for 2025 through 2031. With Antibody-drug Conjugates (ADCs) CMO and CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates (ADCs) CMO and CDMO industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates (ADCs) CMO and CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-drug Conjugates (ADCs) CMO and CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates (ADCs) CMO and CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates (ADCs) CMO and CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates (ADCs) CMO and CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates (ADCs) CMO and CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cleavable linkers
Non-cleavable linkers
Segmentation by Application:
Solid Tumors
Hematological Malignanciesncies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
130 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Player
- 4 Antibody-drug Conjugates (ADCs) CMO and CDMO by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
